Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?

Ann Oncol. 2018 May 1;29(5):1096-1098. doi: 10.1093/annonc/mdy115.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Algorithms
  • Breast Neoplasms*
  • Chemotherapy, Adjuvant
  • Genomics
  • Humans
  • Neoplasm Recurrence, Local